Advanced search
Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 38, 2024 - Issue 5
Submit an article Journal homepage
183
Views
1
CrossRef citations to date
0
Altmetric
Short Communications

Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells

Koji Teshimaa Research & Development Headquarters, Lequio Pharma Co., Ltd, Naha, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3524-100XView further author information
ORCID Icon,
Takeshi Tanakab Interprotein Corporation, Osaka, JapanORCID Iconhttps://orcid.org/0000-0001-9505-9934View further author information
ORCID Icon,
Zhengmao Yeb Interprotein Corporation, Osaka, JapanView further author information
,
Ken Ikedab Interprotein Corporation, Osaka, JapanView further author information
,
Takao Matsuzakib Interprotein Corporation, Osaka, JapanView further author information
,
Tamotsu Shiromaa Research & Development Headquarters, Lequio Pharma Co., Ltd, Naha, JapanView further author information
,
Ayumu Muroyab Interprotein Corporation, Osaka, JapanView further author information
,
Masato Hosodab Interprotein Corporation, Osaka, JapanView further author information
,
Mayo Yasugic Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan;d Asian Health Science Institute, Osaka Metropolitan University, Osaka, Japan;e Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Izumisano, JapanORCID Iconhttps://orcid.org/0000-0002-9688-2006View further author information
ORCID Icon &
Hirotsugu Komatsub Interprotein Corporation, Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-4206-2416View further author information
ORCID Icon show all
Pages 867-872 | Received 28 Nov 2022, Accepted 17 Mar 2023, Published online: 28 Mar 2023

References

  • Coghi P, Yang LJ, Ng JPL, Haynes RK, Memo M, Gianoncelli A, Wong VKW, Ribaudo G. 2021. A drug repurposing approach for antimalarials interfering with SARS-CoV-2 spike protein receptor binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2). Pharmaceuticals (Basel). 14(10):954.
  • Coghi P, Yun XY, Ng JPL, Law BYK, Memo M, Gianoncelli A, Wong VKW, Ribaudo G. 2022. Exploring SARS-CoV-2 delta variant spike protein receptor-binding domain (RBD) as a target for tanshinones and antimalarials. Nat Prod Res. 36(23):6150–6155.
  • Demeke CA, Woldeyohanins AE, Kifle ZD. 2021. Herbal medicine use for the management of COVID-19: a review article. Metabol Open. 12:100141.
  • Goc A, Sumera W, Rath M, Niedzwiecki A. 2021. Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions. PLoS One. 16(6):e0253489.
  • Jena AB, Kanungo N, Nayak V, Chainy GBN, Dandapat J. 2021. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies. Sci Rep. 11(1):8482.
  • Komatsu H, Tanaka T, Ye Z, Ikeda K, Matsuzaki T, Yasugi M, Hosoda M. 2023. Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system. J Biomol Struct Dyn. 41(5):1767–1775.
  • Malabadi RB, Meti NT, Chalannavar RK. 2021. Role of herbal medicine for controlling coronavirus (SARS-CoV-2) disease (COVID-19). Int J Res Sci Innov. 8(2):135–165.
  • Marín-Palma D, Tabares-Guevara JH, Zapata-Cardona MI, Flórez-Álvarez L, Yepes LM, Rugeles MT, Zapata-Builes W, Hernandez JC, Taborda NA. 2021. Curcumin inhibits in vitro SARS-CoV-2 infection in Vero E6 cells through multiple antiviral mechanisms. Molecules. 26(22):6900.
  • Nag A, Paul S, Banerjee R, Kundu R. 2021. In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. Comput Biol Med. 137:104818.
  • Patel A, Rajendran M, Shah A, Patel H, Pakala SB, Karyala P. 2022. Virtual screening of curcumin and its analogues against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV. J Biomol Struct Dyn. 40(11):5138–5146.
  • Rattis BAC, Ramos SG, Celes MRN. 2021. Curcumin as a potential treatment for COVID-19. Front Pharmacol. 12:675287.
  • Ribaudo G, Coghi P, Yang LJ, Ng JPL, Mastinu A, Memo M, Wong VKW, Gianoncelli A. 2022. Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD). Nat Prod Res. 36(20):5358–5363.
  • Shanmugarajan DPP, Kumar BRP, Suresh B. 2020. Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets. RSC Adv. 10(52):31385–31399.
  • Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC, Majeed M, Mohammadi A, Banach M, Jamialahmadi T, Sahebkar A. 2022. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: a systematic review of clinical trials. Nutrients. 14(2):256.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.